In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens

Journal of Clinical Microbiology

Volumn 36, Issue 1, 1998, Pages 198-202

  Espinel Ingroff, Ana ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; CANDIDA; FUNGUS; FUSARIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; YEAST;

AJELLOMYCES CAPSULATUS; AJELLOMYCES DERMATITIDIS; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; BIPOLARIS; BLASTOMYCES; CANDIDA; DIPODASCUS CAPITATUS; FILOBASIDIELLA NEOFORMANS; FUNGI; FUSARIUM; FUSARIUM OXYSPORUM; FUSARIUM SOLANI; PICHIA ANOMALA; PSEUDALLESCHERIA BOYDII; RHIZOPUS ORYZAE; RHODOTORULA MUCILAGINOSA; SACCHAROMYCES CEREVISIAE; SPORIDIOBOLUS SALMONICOLOR; SPOROTHRIX SCHENCKII; TRICHOSPORON BEIGELII;

EID: 0031974507     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.36.1.198-202.1998     Document Type: Article

References (32)

1. Anaissie, E. 1992. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin. Infect. Dis. 14:S43-S53.
2. Bailey, E. M., D. J. Krakovsky, and M. J. Rybak. 1990. The triazole antifungal agents: a review of itraconazole and fluconazole. Pharmacotherapy 10:146-153.
3. Barchiesi, F., M. Restrepo, D. A. McGough, and M. G. Rinaldi. 1995. In vitro activity of a new antifungal triazole: UK-109,496. abstr. F71, p.125. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
4. Barry, A. L., and S. D. Brown. 1996. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob. Agents Chemother. 40:1948-1949.
5. Denning, D., A. de Favero, E. Gluckman, D. Norfolk, M. Ruhnke, S. Yonren, P. Troke, and N. Sarantis. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in acute invasive aspergillosis, abstr. F80, p. 126. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
6. Dixon, D. M., M. M. McNeil, M. L. Cohen, B. G. Gellin, and J. R. La Montagne. 1996. Fungal infections: a growing threat. Public Health Rep. 111:226-235.
7. Donabedian, H., E. O'Donnell, C. Olszewski, R. D. MacArthur, and N. Budd. 1994. Disseminated cutaneous and meningeal sporotrichosis in an AIDS patient. Diagn. Microbiol. Infect. Dis. 18:111-115.
8. Dupont, B., D. Denning, H. Lode, S. Yonren, P. Troke, and N. Sarantis. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in chronic invasive aspergillosis. abstr. F81, p. 127. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
9. Espinel-Ingroff, A., M. Bartlett, R. Bowden, N. X. Chin, C. Cooper, Jr., A. Fothergill, M. R. McGinnis, P. Menezes, S. A. Messer, P. W. Nelson, F. C. Odds, L. Pasarell, J. Peter, M. A. Pfaller, J. H. Rex, M. G. Rinaldi, G. S. Shankland, T. J. Walsh, and I. Weitzman. 1997. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J. Clin. Microbiol. 35:139-143.
10. Espinel-Ingroff, A., K. Dawson, M. Pfaller, E. Anaissie, B. Breslin, D. Dixon, A. Fothergill, V. Paetznick, J. Peter, M. Rinaldi, and T. Walsh. 1995. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob. Agents Chemother. 39:314-319.
11. Espinel-Ingroff, A., C. W. Kish, Jr., T. M. Kerkering, K. Bartizal, R. Fromtling, J. N. Galgiania, K. Villareal, M. A. Pfaller, T. Gerarden, M. G. Rinaldi, and A. Fothergill. 1992. A collaborative comparison of broth macro-and microdilution antifungal susceptibility tests. J. Clin. Microbiol. 30:3138-3145.
12. Fraser, V. J., M. Jones, J. Dunkel, S. Storfer, G. Medoff, and W. C. Dunagan. 1992. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin. Infect. Dis. 15:414-421.
13. Fromtling, R. A. 1988. Overview of medically important antifungal azole derivatives. Clin. Microbiol. Rev. 1:187-217.
14. Hadley, S., and A. W. Karchmer. 1995. Fungal infections in solid organ transplant recipients. Infect. Dis. Clin. N. Am. 9:1045-1074.
15. Hay, R. J. 1991. Antifungal therapy and the new azole compounds. J. Antimicrob. Chemother. 28(Suppl. A):35-46.
16. Hazen, K. 1995. New and emerging yeast pathogens. Clin. Microbiol. Rev. 8:462-475.
17. Hitchcock, C. A., R. J. Andrews, B. G. H. Lewis, and P. F. Troke. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity in experimental infections with Cryptococcus, abstr. F75, p.126. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
18. Hitchcock, C. A., R. J. Andrews, B. G. H. Lewis, and P. F. Troke. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity in experimental infections with Aspergillus, abstr. F74, p.125. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
19. Jarvis, W. R. 1995. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin. Infect. Dis. 20:1526-1530.
20. Khoo, S. H., and D. W. Denning. 1994. Invasive aspergillosis in patients with AIDS. Clin. Infect. Dis. 19:S41-S48.
21. McGinnis, M. R. 1974. Storage of stock cultures of filamentous fungi, yeasts, and some aerobic actinomycetes in sterile, distilled water. Appl. Microbiol. 28:218-222.
22. McGinnis, M. R., L. Pasarell, and C. R. Cooper, Jr. 1995. In vitro susceptibility of clinical mould isolates to UK-109,496, amphotericin B, fluconazole, and itraconazole. abstr. E76, p.99. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
23. Morrison, V. A., R. J. Haake, and D. J. Weisdorf. 1993. The spectrum on non-Candida fungal infections following bone marrow transplantation. Medicine 72:78-89.
24. Murphy, M., E. M. Bernard, T. Ishimaru, and D. Armstrong. 1997. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 41:696-698.
25. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. M-27A. National Committee for Clinical Laboratory Standards, Villanova, Pa.
26. Nguyen, M. H., J. E. Peacock, Jr., A. J. Morris, D. C. Tanner, M. L. Nguyen, D. R. Snydman, M. M. Wagener, M. G. Rinaldi, and V. L. Yu. 1996. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 100:617-623.
27. Patterson, T. F., V. T. Andriole, M. J. Zervos, D. Therasse, and C. A. Kauffman. 1990. The epidemiology of pseudallescheriasis complicating transplantation: nosocomial and community-acquired infection. Mycoses 33:297-302.
28. Radford, S. A., E. M. Johnson, and D. W. Warnock. 1997. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob. Agents Chemother. 41:841-843.
29. Rex, J. H., P. W. Nelson, V. L. Paetznick, M. Lozano-Chiu, A. Espinel-Ingroff, and E. J. Anaissie. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob. Agents Chemother., in press.
30. Ruhnke, M., A. Schmidt-Westhausen, and M. Trautmann. 1997. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 41:575-577.
31. Troke, P. F., A. S. Bell, R. P. Dickinson, C. A. Hitchcock, S. Jezequel, S. Narayanaswami, S. J. Ray, and K. Richardson. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: discovery and antifungal properties, abstr. F70, p.125. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
32. Walsh, T. J., C. Gonzalez, E. Roilides, B. U. Mueller, N. Ali, L. L. Lewis, T. O. Whitcomb, D. J. Marshall, and P. A. Pizzo. 1995. Fungemia in children infected with the human immunodeficiency virus: new epidemiologic patterns, emerging pathogens, and improved outcome with antifungal therapy. Clin. Infect. Dis. 20:900-906.